公开(公告)号：US20240425521A1

公开(公告)日：2024-12-26

申请号：US18679695

申请日：2024-05-31

Applicant: H. Lundbeck A/S

Inventor： Karsten Juhl ,  Wanwan Yu ,  Thomas Leegaard Andersen ,  Erhad Ascic ,  Michael Baek ,  Gitte Kobberøe Mikkelsen ,  Andreas Michael Arnold ,  Anders Højgaard Hansen ,  Petra Lindovská ,  Henrik Juhani Keränen ,  Ferran Planas Padrós

IPC: C07D498/14 ,  A61K31/424 ,  A61K31/4245 ,  A61K31/429 ,  A61K31/437 ,  A61K31/519 ,  C07D498/04 ,  C07D513/04

Abstract: The present invention relates to novel spiro-macrocyclic compounds of general formula (I) which are Orexin 2 receptor agonists.

公开(公告)号：US11993612B2

公开(公告)日：2024-05-28

申请号：US18331289

申请日：2023-06-08

Applicant: H. Lundbeck A/S

Inventor： Thomas Jensen ,  Mikkel Jessing ,  Wanwan Yu ,  David Rodriguez Diaz ,  Jacob Nielsen ,  Christopher Richard Jones ,  Thomas Andersen ,  Mikkel Fog Jacobsen

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07B2200/05

Abstract: The present invention is directed to compounds of formula I




The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.

公开(公告)号：US20230416272A1

公开(公告)日：2023-12-28

申请号：US18331289

申请日：2023-06-08

Applicant: H. Lundbeck A/S ,  Vernalis (R&D) Limited

Inventor： Thomas Jensen ,  Mikkel Jessing ,  Wanwan Yu ,  David Rodriguez Diaz ,  Jacob Nielsen ,  Christopher Richard Jones ,  Thomas Andersen ,  Mikkel Fog Jacobsen

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07B2200/05

Abstract: The present invention is directed to compounds of formula I




The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.

公开(公告)号：US11780851B2

公开(公告)日：2023-10-10

申请号：US18049802

申请日：2022-10-26

Applicant: H. Lundbeck A/S ,  Vernalis (R&D) Limited

Inventor： Thomas Jensen ,  Mikkel Jessing ,  Wanwan Yu ,  David Rodriguez Diaz ,  Jacob Nielsen ,  Christopher Richard Jones ,  Thomas Andersen ,  Mikkel Fog Jacobsen

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07B2200/05

Abstract: The present invention is directed to compounds of formula I




The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.